Six Eminent Cancer Researchers Advise Agendia
AMSTERDAM, October 29 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics has appointed six members to its Clinical and Scientific Advisory Board. The newly established Clinical and Scientific Advisory Board is comprised of internationally-recognized scientists with research and clinical expertise. The advisors review early research programs and provide critical evaluations from academic and clinical perspectives.
Piet Borst (chair), M.D., PhD, CBE, For Mem RS, Staff Member and Emeritus Director of the Netherlands Cancer Institute and Professor of Clinical Biochemistry, Amsterdam, The Netherlands
Jose Baselga M.D., Professor of Medicine and Chairman of the medical oncology service, Vall d'Hebron University Hospital, Barcelona, Spain
Matt van de Rijn, M.D., Ph.D, Professor of Pathology, Stanford University, School of Medicine, Stanford, CA, USA
David Kerr M.D., Professor of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford, UK
C. Kent Osborne, M.D., Professor of Medicine and, Director, Breast Center Baylor College of Medicine, Houston, Texas, USA, Director, Dan L. Duncan Cancer Center at Baylor College of Medicine
Joe W. Gray, Ph.D., Director, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA and Professor UCSF Comprehensive Cancer Center.
"We are very pleased that this outstanding group of scientist-clinicians has agreed to join Agendia's clinical and scientific advisory board", says Prof. dr. Rene Bernards, Chief Scientific Officer at Agendia. "Their insights into the clinical needs of cancer patients will help us to tailor our product portfolio to best serve patients and their doctors to optimize the treatment for each individual patient."
"The addition of these six distinguished scientists and clinicians will enable us to further strengthen strategies in cancer and other diseases" said Dr. Bernhard Sixt, Chief Executive Officer at Agendia.
Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to obtain FDA approval for it's breast cancer test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)*, is a diagnostic test to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary". Agendia recently also presented its new colon cancer prognosis profile, ColoPrint(R), which is currently undergoing further validation. Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology.
* CupPrint(R) is based on a license to the TUO database of AviaraDx
|SOURCE Agendia BV|
Copyright©2007 PR Newswire.
All rights reserved